Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings (HRMY)
NASDAQ:HRMY
Total Valuation
Harmony Biosciences Holdings has a market cap or net worth of $2.05B. The enterprise value is $1.17B.
Market Cap$2.05B
Enterprise Value$1.17B
Share Statistics
Harmony Biosciences Holdings has 57,596,360 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding57,596,360
Owned by Insiders1.04%
Owned by Institutions15.42%
Financial Efficiency
Harmony Biosciences Holdings’s return on equity (ROE) is 0.22 and return on invested capital (ROIC) is 17.20%.
Return on Equity (ROE)0.22
Return on Assets (ROA)0.15
Return on Invested Capital (ROIC)17.20%
Return on Capital Employed (ROCE)0.23
Revenue Per Employee2.67M
Profits Per Employee542.88K
Employee Count268
Asset Turnover0.72
Inventory Turnover21.79
Valuation Ratios
The current PE Ratio of Harmony Biosciences Holdings is 11.2. Harmony Biosciences Holdings’s PEG ratio is 0.75.
PE Ratio11.2
PS Ratio2.74
PB Ratio2.97
Price to Fair Value2.97
Price to FCF8.95
Price to Operating Cash Flow6.94
PEG Ratio0.75
Income Statement
In the last 12 months, Harmony Biosciences Holdings had revenue of 714.73M and earned 145.49M in profits. Earnings per share was 2.56.
Revenue714.73M
Gross Profit557.92M
Operating Income190.83M
Pretax Income191.80M
Net Income145.49M
EBITDA233.41M
Earnings Per Share (EPS)2.56
Cash Flow
In the last 12 months, operating cash flow was 297.61M and capital expenditures -716.00K, giving a free cash flow of 296.89M billion.
Operating Cash Flow297.61M
Free Cash Flow296.89M
Free Cash Flow per Share5.15
Dividends & Yields
Harmony Biosciences Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.09
52-Week Price Change2.57%
50-Day Moving Average29.86
200-Day Moving Average32.82
Relative Strength Index (RSI)74.64
Average Volume (3m)911.28K
Important Dates
Harmony Biosciences Holdings upcoming earnings date is Mar 3, 2026, Before Open (Confirmed).
Last Earnings DateNov 4, 2025
Next Earnings DateMar 3, 2026
Ex-Dividend Date―
Financial Position
Harmony Biosciences Holdings as a current ratio of 3.31, with Debt / Equity ratio of 20.32%
Current Ratio3.31
Quick Ratio3.27
Debt to Market Cap0.09
Net Debt to EBITDA-1.16
Interest Coverage Ratio10.91
Taxes
In the past 12 months, Harmony Biosciences Holdings has paid 46.31M in taxes.
Income Tax46.31M
Effective Tax Rate0.24
Enterprise Valuation
Harmony Biosciences Holdings EV to EBITDA ratio is 7.22, with an EV/FCF ratio of 7.71.
EV to Sales2.36
EV to EBITDA7.22
EV to Free Cash Flow7.71
EV to Operating Cash Flow7.67
Balance Sheet
Harmony Biosciences Holdings has $672.58M in cash and marketable securities with $169.73M in debt, giving a net cash position of $502.85M billion.
Cash & Marketable Securities$672.58M
Total Debt$169.73M
Net Cash$502.85M
Net Cash Per Share$8.73
Tangible Book Value Per Share$9.60
Margins
Gross margin is 77.70%, with operating margin of 26.70%, and net profit margin of 20.36%.
Gross Margin77.70%
Operating Margin26.70%
Pretax Margin26.84%
Net Profit Margin20.36%
EBITDA Margin32.66%
EBIT Margin29.28%
Analyst Forecast
The average price target for Harmony Biosciences Holdings is $46.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$46.00
Price Target Upside29.36% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast21.13%
EPS Growth Forecast50.86%